# EMaBS TB Vaccine Study

> **NCT03681860** · PHASE1,PHASE2 · COMPLETED · sponsor: **University of Oxford** · enrollment: 72 (actual)

## Conditions studied

- Safety
- Immunogenicity

## Interventions

- **BIOLOGICAL:** ChAdOx185A
- **BIOLOGICAL:** MVA85A
- **BIOLOGICAL:** BCG

## Key facts

- **NCT ID:** NCT03681860
- **Lead sponsor:** University of Oxford
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-07-01
- **Primary completion:** 2021-05-24
- **Final completion:** 2021-05-24
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2022-08-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03681860

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03681860, "EMaBS TB Vaccine Study". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03681860. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*